.

For patients with IC, relief cannot come soon enough. Early diagnosis and prompt initiation of appropriate therapy may provide relief of bladder pain and discomfort for those suffering from this painful condition.1

IC pain relief. It's about time.

ELMIRON® should be considered as part of a multimodal approach to therapy.


At diagnosis of IC, it's time for ELMIRON®

ELMIRON® is the only FDA-approved oral therapy for the relief of bladder pain and discomfort associated with interstitial cystitis

  • ELMIRON® provides proven efficacy
    • In an open-label study, 61% of patients on monotherapy experienced improvement in symptoms at 3 months on therapy (n=1192)*
    • In a separate, double-blind, placebo-controlled study, 38% of patients with IC taking 300 mg/day reported at 3 months a greater than 50% improvement in bladder pain compared to 18% of patients taking placebo†
  • Symptom relief with ELMIRON® is gradual and may require 3 to 6 months of continuous therapy
  • ELMIRON® is generally well tolerated


*1192 of 2499 patients received treatment for 3 months.
†N=128 patients in 300-mg/day group. PORIS response is based on all patients, not completers.



Important Safety Information

  • Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
  • Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
  • Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
  • Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
  • Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)


    Reference:
  1. Nickel JC, Kaufman DM, Zhang HF, Wan GJ, Sand PK. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008;71:57-61.